Importantly, GSDMD activation in intratumoral CD4+ T lymphocytes correlates with survival benefit and immunotherapy efficacy in colorectal cancer and pancreatic adenocarcinoma. This evidence concerns the gene CD4 and pancreatic adenocarcinoma.